AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23042930 — intervention group
Group type: COMPARATOR
Intervention: 2D-T2WI
Number of subjects: 37
Study 23042930 — intervention group
Group type: COMPARATOR
Intervention: 3D-T1WI
Number of subjects: 37
Study 19960351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training using water-resistance equipment (90 min, 3 times per week for 8 weeks)
Number of subjects: 20
Study 19960351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training using water-resistance equipment
Number of subjects: 20
Study 19960351 — intervention group
Group type: COMPARATOR
Intervention: Non-resistance group (without water-resistance equipment)
Number of subjects: 20
Study 19001024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42418
Study 19001024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amlodipine/lisinopril
Number of subjects: 42418
Study 19001024 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone/doxazosin
Number of subjects: 42418
Study 17000226 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release (CR)-melatonin 2 mg
Number of subjects: 38
Study 17000226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 14666011 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulatory arrest
Number of subjects: 155
Study 14666011 — intervention group
Group type: COMPARATOR
Intervention: Low-flow bypass
Number of subjects: 155
Study 11200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed conjugated estrogens (CEE)
Number of subjects: 875
Study 11200306 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus continuous medroxyprogesterone (MPA)
Number of subjects: 875
Study 11200306 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus cyclical MPA
Number of subjects: 875
Study 11200306 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus cyclical micronised progesterone
Number of subjects: 875
Study 11200306 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug treatment groups
Number of subjects: 875
Study 11200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups
Number of subjects: 875
Study 11200306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 8800590 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 7
Study 8800590 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone plus vasopressin (AVP)
Number of subjects: 7
Study 8800590 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone plus alprazolam
Number of subjects: 7
Study 1629380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone, mean daily dose 235 +/- 10 mg, 10 weeks
Number of subjects: 21
Study 1629380 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 10 weeks
Number of subjects: 21
Study 1629380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 21
Study 1629380 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine and fluoxetine
Number of subjects: 21
Study 6380301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium diet (300 mg calcium/day)
Number of subjects: 10
Study 6380301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (2 gm sodium/day)
Number of subjects: 10
Study 6380301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium diet plus hydrochlorthiazide (25 mg twice a day)
Number of subjects: 10
Study 6380301 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital diet
Number of subjects: 10
Study 31904890 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based care (SC)
Number of subjects: 40
Study 31904890 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 40
Study 29882811 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Energy Breakfast (HE-BF)
Number of subjects: 13
Study 29882811 — intervention group
Group type: COMPARATOR
Intervention: Low-Energy Breakfast (LE-BF)
Number of subjects: 13
Study 26343747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham SM (5% of pain pressure threshold)
Number of subjects: 32
Study 26343747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure SM (40% of pain pressure threshold)
Number of subjects: 32
Study 26343747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure SM (80% of pain pressure threshold)
Number of subjects: 32
Study 26343747 — intervention group
Group type: COMPARATOR
Intervention: Control (no touch)
Number of subjects: 32
Study 24154834 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated email notification system
Number of subjects: 441
Study 22285555 — intervention group
Group type: EXPERIMENTAL
Intervention: Session R (emotionally neutral task)
Number of subjects: 81
Study 22285555 — intervention group
Group type: EXPERIMENTAL
Intervention: Session T (moderately threatening task)
Number of subjects: 81
Study 22285555 — intervention group
Group type: EXPERIMENTAL
Intervention: Session T (ineffective T: iT subsample, n=15)
Number of subjects: 81
Study 22285555 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HR and HRV between sessions and groups
Number of subjects: 81
Study 20354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 267
Study 18388340 — intervention group
Group type: EXPERIMENTAL
Intervention: sarpogrelate (100 mg TID)
Number of subjects: 1510
Study 18388340 — intervention group
Group type: COMPARATOR
Intervention: aspirin (81 mg/d)
Number of subjects: 1510
Study 15807810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutometer standard R-parameters and new area parameters (R3, R4, R9, F2, F3)
Number of subjects: 40
Study 12955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow synovectomy
Number of subjects: 120
Study 12955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovectomy with radial head resection
Number of subjects: 120
Study 12955196 — intervention group
Group type: COMPARATOR
Intervention: Both groups (synovectomy and synovectomy with radial head resection)
Number of subjects: 120
Study 10394512 — intervention group
Group type: EXPERIMENTAL
Intervention: Defecography
Number of subjects: 125
Study 10394512 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 125
Study 8679834 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral S-adenosylmethionine (SAMe)
Number of subjects: 45
Study 8679834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1726758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine and acyclovir (joint application)
Number of subjects: 636
Study 1726758 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir alone
Number of subjects: 636
Study 1726758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine only
Number of subjects: 636
Study 1726758 — intervention group
Group type: COMPARATOR
Intervention: Palliative treatment only
Number of subjects: 636
Study 1726758 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative and isoprinosine treatment
Number of subjects: 636
Study 1726758 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative and acyclovir treatment
Number of subjects: 636
Study 1726758 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (palliative, isoprinosine, and acyclovir)
Number of subjects: 636
Study 6219903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet containing orphenadrine citrate and paracetamol ('Norgesic')
Number of subjects: 0
Study 6219903 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol alone
Number of subjects: 0
Study 30955572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-frequency oscillatory ventilation (NHFOV)
Number of subjects: 206
Study 30955572 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 206
Study 28353116 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-unit RCI twice a week
Number of subjects: 16
Study 28353116 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-unit RCI twice a week
Number of subjects: 16
Study 28353116 — intervention group
Group type: COMPARATOR
Intervention: 80-unit RCI
Number of subjects: 16
Study 28353116 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 16
Study 28353116 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 25583157 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP-CV (systolic blood pressure coefficient of variation)
Number of subjects: 24593
Study 25583157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HR (heart rate)
Number of subjects: 24593
Study 25583157 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP-CV and Mean HR
Number of subjects: 24593
Study 25583157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 24593
Study 25583157 — intervention group
Group type: EXPERIMENTAL
Intervention: Important cognitive decline
Number of subjects: 24593
Study 25583157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive deterioration
Number of subjects: 24593
Study 23343372 — intervention group
Group type: COMPARATOR
Intervention: Cemented DLC all‐polyethylene cup (C)
Number of subjects: 28
Study 23343372 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented hydroxyapatite‐coated chrome‐cobalt Elektra screw cup (UC)
Number of subjects: 28
Study 21403790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 40
Study 21403790 — intervention group
Group type: COMPARATOR
Intervention: Prazosin 1‐2 mg
Number of subjects: 40
Study 18080763 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a (44 microg, 12 MIU)
Number of subjects: 26
Study 18080763 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a plus RBV (1,000‐1,200 mg/day)
Number of subjects: 26
Study 18080763 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a
Number of subjects: 26
Study 18080763 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a plus RBV
Number of subjects: 26
Study 16418617 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 89
Study 16418617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 12891605 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 79
Study 12891605 — intervention group
Group type: COMPARATOR
Intervention: Predilation
Number of subjects: 79
Study 11306831 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacalcitol
Number of subjects: 9
Study 11306831 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 9
Study 9209899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms (Group A)
Number of subjects: 49
Study 9209899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms (Group B)
Number of subjects: 49
Study 9209899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms plus Norethisterone 1.2 mg (Group C)
Number of subjects: 49
Study 8132186 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment for one year
Number of subjects: 30
Study 3549802 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil
Number of subjects: 149
Study 3549802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil
Number of subjects: 149
Study 3549802 — intervention group
Group type: COMPARATOR
Intervention: Placebo to 3% minoxidil crossover
Number of subjects: 149
Study 3549802 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (2% minoxidil, 3% minoxidil, placebo to 3% crossover)
Number of subjects: 149
Study 3549802 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil
Number of subjects: 149
Study 29066586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation (MI-E)
Number of subjects: 22
Study 29066586 — intervention group
Group type: COMPARATOR
Intervention: Conventional Chest Physiotherapy (CPT)
Number of subjects: 22
Study 27440463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of enoxaparin according to anti-factor Xa levels
Number of subjects: 144
Study 27440463 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 40 mg daily enoxaparin
Number of subjects: 144
Study 23941101 — intervention group
Group type: EXPERIMENTAL
Intervention: Himalayan singing bowl (HSB)
Number of subjects: 51
Study 23941101 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 51
Study 24547662 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-seeking process in older adults with CG
Number of subjects: 8
Study 21142609 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg/day transdermal testosterone patch (TTP)
Number of subjects: 967
Study 18083543 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity at baseline
Number of subjects: 1955
Study 18083543 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity at follow-up
Number of subjects: 1955
Study 16531443 — intervention group
Group type: EXPERIMENTAL
Intervention: Response entropy before skin incision
Number of subjects: 40
Study 16531443 — intervention group
Group type: EXPERIMENTAL
Intervention: State entropy before skin incision
Number of subjects: 40
Study 16531443 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS before skin incision
Number of subjects: 40
Study 16531443 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG variables (response entropy, state entropy) with increases in electrical stimulation
Number of subjects: 40
Study 16531443 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between response entropy and state entropy with increases in electrical stimulation
Number of subjects: 40
Study 16531443 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG variables differentiating intensity of electrical stimulation
Number of subjects: 40
Study 14723338 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend of partially purified Yucca schidigera and Quillaja saponaria extracts (0.9 mg daily for 4 weeks)
Number of subjects: 0
Study 11078048 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, computer-assisted dietary goal-setting intervention
Number of subjects: 320
Study 11078048 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up calls
Number of subjects: 320
Study 11078048 — intervention group
Group type: COMPARATOR
Intervention: Community resources enhancement
Number of subjects: 320
Study 8732309 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-1200 mg of CX516
Number of subjects: 48
Study 8732309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1349049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (four 1 g Pikasol capsules containing 2.7 g n‐3 fatty acids per day)
Number of subjects: 533
Study 1349049 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (four 1 g capsules per day)
Number of subjects: 533
Study 1349049 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 533
Study 3945704 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafoveal condition (stimuli appeared laterally in one visual hemifield)
Number of subjects: 0
Study 3945704 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal condition (stimuli appeared centrally on the fovea)
Number of subjects: 0
Study 29084391 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLLING (4 sets of 90‐s rolling massage)
Number of subjects: 26
Study 29084391 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (rest)
Number of subjects: 26
Study 25864194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trandolapril (1 mg, 2 mg, 4 mg)
Number of subjects: 12
Study 25864194 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose trandolapril (2 mg/day for 6 days)
Number of subjects: 12
Study 25864194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trandolapril
Number of subjects: 12
Study 25864194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple doses of trandolapril
Number of subjects: 12
Study 24193173 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube (P)
Number of subjects: 90
Study 24193173 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire reinforced tube with posteriorly positioned tip bevel (WRP)
Number of subjects: 90
Study 24193173 — intervention group
Group type: COMPARATOR
Intervention: Wire reinforced tube with anteriorly positioned tip bevel (WRA)
Number of subjects: 90
Study 21597980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 117
Study 21597980 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 117
Study 20090547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrepide trapidil‐eluting stent
Number of subjects: 40
Study 20090547 — intervention group
Group type: COMPARATOR
Intervention: Taxus paclitaxel‐eluting stent
Number of subjects: 40
Study 18333870 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (doses ranged from 3 mg b.i.d. to 600 mg q.d.)
Number of subjects: 88
Study 18333870 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 88
Study 17187540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed electronic messages intervention
Number of subjects: 912
Study 17187540 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 912
Study 14575630 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI Dental Implant System
Number of subjects: 24
Study 14575630 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern Implant System
Number of subjects: 24
Study 11221289 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 10 mg
Number of subjects: 397
Study 11221289 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 397
Study 11221289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with enalapril (up to 10 mg once daily)
Number of subjects: 397
Study 11221289 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 397
Study 11221289 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 397
Study 8677286 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow paced breathing (8 cpm)
Number of subjects: 30
Study 8677286 — intervention group
Group type: COMPARATOR
Intervention: Fast paced breathing (30 cpm)
Number of subjects: 30
Study 8677286 — intervention group
Group type: COMPARATOR
Intervention: Nonpaced breathing (spontaneous)
Number of subjects: 30
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional schedule (days 0, 28, 300)
Number of subjects: 379
Study 1557929 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated schedule (days 0, 7, 21)
Number of subjects: 379
Study 4093346 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (4 X 2 g for 48 h)
Number of subjects: 40
Study 30599899 — intervention group
Group type: EXPERIMENTAL
Intervention: EGP (200 mg, twice a day)
Number of subjects: 72
Study 30599899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 28124589 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Number of subjects: 213
Study 26343476 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 195
Study 26343476 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV positive status
Number of subjects: 195
Study 26343476 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving food assistance
Number of subjects: 195
Study 26343476 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of health problems
Number of subjects: 195
Study 24261301 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermopaste application at Shenque (CV 8) 0.5 hours before PPH
Number of subjects: 100
Study 24261301 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermopaste application at Shenque (CV 8) 1.0 hours before PPH
Number of subjects: 100
Study 24261301 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermopaste application at Shenque (CV 8) at the time of PPH (0 h)
Number of subjects: 100
Study 24261301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 100
Study 21726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI) delivered by an Alcohol Specialist Nurse (ASN)
Number of subjects: 130
Study 21726445 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 130
Study 21726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI)
Number of subjects: 130
Study 19695387 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg (followed by 200 mg q12h)
Number of subjects: 303
Study 19695387 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg (followed by 550 mg q12h)
Number of subjects: 303
Study 19695387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 19695387 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg (study 2 only)
Number of subjects: 303
Study 16544756 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic drug 'Avia-more'
Number of subjects: 0
Study 16544756 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 0
Study 14557430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral weekly ibandronate (20 mg)
Number of subjects: 235